What question did this study set out to answer?

This research examines how the revised FIGO 2018 staging system influences survival outcomes in cervical cancer patients.

April 1, 2026Open Access

Impact of the revised FIGO 2018 staging system on survival outcomes with respect to prognostic factors in cervical cancer patients treated in a tertiary care cancer center in South Karnataka

Key Points

This research examines how the revised FIGO 2018 staging system influences survival outcomes in cervical cancer patients.
Analyzed survival data of cervical cancer patients treated at a tertiary care cancer center.
Compared outcomes across different FIGO stages, particularly focusing on IIIC1, IIIB, IIIC2, and IVA.
Identified prognostic factors associated with survival variations.
Stage IIIC1 exhibited better survival outcomes than stage IIIB.
Stage IIIC2 demonstrated worse outcomes compared to stage IVA.
Variability in survival by stage underscores the need for improved treatment strategies, especially for node-positive disease.

Abstract

The FIGO 2018 staging effectively reflects survival variation in cervical cancer. Notably, stage IIIC1 had better outcomes than IIIB, while IIIC2 had worse outcomes compared to IVA. Further studies are needed to refine treatment for node-positive disease.

Impact of the revised FIGO 2018 staging system on survival outcomes with respect to prognostic factors in cervical cancer patients treated in a tertiary care cancer center in South Karnataka

Key Points

Abstract

Cite This Study